In this webinar, Max Haberbusch, PhD and Esra Neufeld, PhD explore closed-loop cardiac rhythm control restoration in heart-transplant patients from model development to in silico regulatory evidence for safety and efficacy trials.
The NIH SPARC program pursues the ambitious goal to rapidly advance the promising field of bioelectronic medicine. This not only includes funding over 100 research teams to perform comprehensive mapping of the autonomic peripheral nervous system and its interaction with organ physiology, but also establishes a large infrastructure for FAIR data sharing, collaborative and reproducible modeling, mapping and knowledge management, to supercharge the field.
After briefly introducing SPARC and its infrastructure, this webinar illustrates how the NeuHeart consortium - an independent European research initiative - has leveraged that infrastructure in its quest to restore closed-loop cardiac rhythm control to heart-transplant patients.
The webinar discusses:
- Hybrid electromagnetic (EM-)electrophysiological modeling of neural interfaces, including model-based stimulation selectivity optimization and neural sensing information content maximization;
- A comprehensive model of cardiovascular regulation and its experimental validation; and
- Integration of these independently developed neural interface and cardiovascular regulation models, along with a generic closed-loop control framework.
The end provides a view on the ongoing research on model-based intelligent control and in silico regulatory evidence and trials for safety and efficacy assessment.
Presenters
Max Haberbusch
Max Haberbusch, PhD is an enthusiastic academic who has made significant contributions to the field of vagus nerve stimulation for cardiac applications. Currently serving as a postdoc at the Center for Medical Physics and Biomedical Engineering at the Medical University of Vienna, Dr. Haberbusch is involved in investigating the development and simulation of cardiovascular devices and hemodynamics for diagnostic and therapeutic tools in the field of cardiovascular dynamics.
Esra Neufeld
Esra Neufeld, PhD is the Associate Director and Head of Computational Life Sciences at the IT’IS Foundation in Zurich where he is responsible for the development of the multi-physics simulation platform Sim4Life. As a founding member of the SPARC Data and Resource Center, IT’IS develops and maintains o<sup>2</sup>S<sup>2</sup>PARC, a comprehensive, intuitive, freely accessible online platform to simulate and study nerve electrophysiology and its interaction with organ physiology in a precise and predictive manner.
Sponsor
SPARC Data and Resource Centre
Content Partners
American Physiological Society
About APS
Mission: To advance scientific discovery, understand life, and improve health. Vision: A global multidisciplinary community of scientists solving the major problems affecting life and health. Founded in 1887, the American Physiological Society is a global leader in expanding knowledge related to biological function. We connect a multidisciplinary community of nearly 10,000 scientists and educators from around the world, driving collaboration and spotlighting scientific discoveries in physiology and related disciplines. Our members are advancing treatments and cures for everything from cancer and heart disease, to obesity and addiction. They are also deepening our insight into living organisms generally, helping us to better understand how things like climate change are affecting the world around us. The Society serves this dynamic community in many ways, including:- Publishing 16 globally recognized scholarly journals and a highly-regarded book monograph series;
- Sponsoring scientific meetings and symposia that explore the frontiers of bio-medical science;
- Advocating for science-smart public policy that benefits both our members and the public;
- Bestowing hundreds of awards, grants, and fellowships that recognize scientific excellence and promise;
- Championing physiology education and educators, to support bigger discoveries and better clinical outcomes;
- And providing career resources and other career services, ensuring that all our members have a pathway to success.
Society for Neuroscience
- Advance scientific exchange;
- Support the neuroscience community;
- Educate and engage the public; and
- Advocate for the field.
Federation of European Neuroscience Societies
Federation of European Neuroscience Societies (FENS) is the voice of European neuroscience.
Founded in 1998 at the first Forum of European Neuroscience, the FENS is the main organization for neuroscience in Europe. FENS currently represents 44 national and single-discipline neuroscience societies across 33 European countries and more than 22,000 member scientists.
FENS promotes neuroscience research to policy-makers, funding bodies and the general public, both regionally and internationally. FENS promotes excellence in neuroscience research and facilitates exchanges and networking between neuroscientists within the European Research Area and beyond. FENS was created to bring together the scientific community and advance research and education in neuroscience in Europe and beyond.
FENS believes in inclusive, responsible science. FENS takes great pride in its position as the voice of European neuroscience and strives to structure its activities around the following principles.
American Autonomic Society
The American Autonomic Society (AAS) has been established to bring together individuals from diverse disciplines who share an interest in the structure and function of the autonomic nervous system and in the pathology, treatment, and prevention of its disorders. The Society sponsors annual meetings and provides a point of contact among the many interested clinical and basic scientists who wish to communicate across disciplinary lines.
The AAS began informally in 1990 at Vanderbilt University in Nashville, Tennessee. Important motivating force for the initial meeting were Dr. David Robertson and Ms. Dorothy Trainor-Kingsbury (Shy-Drager Support Group). The Society was formally established in 1992, and Dr. Robertson became its first president. The broad aim of the AAS is to provide a vehicle for investigators and clinicians interested in the autonomic nervous system to interact. It aims to promote research, education, and the academic practice in the autonomic disorders. The Society has escalated in its membership, successfully obtained tax-exempt status, adopted a formal charter, and has its own journal (Clinical Autonomic Research).
The Society has an American infrastructure but a strongly international character. Its membership is open to persons of all countries who share the same interests. During the past quarter century, the AAS has expanded from less than 50 members in 1992 to over 150 members today, focusing on both clinical and basic science, and has taken on a new role in the education of physicians in autonomic disorders. The collegial atmosphere and ongoing collaborative efforts has sparked several important discoveries that directly impact the lives of people with autonomic disorders. Partnerships with support groups have expanded the reach of the AAS into the public eye, while partnerships with industry have culminated in approval of new therapies for people with autonomic disorders.
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
